www.marijuanamoment.net
Open in
urlscan Pro
172.67.214.33
Public Scan
URL:
https://www.marijuanamoment.net/feds-announce-plan-to-fund-research-on-using-psychedelics-to-treat-chronic-pain-in-older-adults/
Submission: On April 29 via manual from US — Scanned from US
Submission: On April 29 via manual from US — Scanned from US
Form analysis 3 forms found in the DOM
GET https://www.marijuanamoment.net/
<form method="get" id="searchform" action="https://www.marijuanamoment.net/">
<input type="text" name="s" id="s" value="Search" onfocus="if (this.value == "Search") { this.value = ""; }" onblur="if (this.value == "") { this.value = "Search"; }">
<input type="hidden" id="searchsubmit" value="Search">
</form>POST
<form id="mc4wp-form-2" class="mc4wp-form mc4wp-form-869" method="post" data-id="869" data-name="Marijuana News In Your Inbox">
<div class="mc4wp-form-fields">Get our daily newsletter. <p>
<label>Email address: </label>
<input type="email" name="EMAIL" placeholder="Your email address" required="">
</p>
<p>
<input type="submit" value="Sign up">
</p>
</div><label style="display: none !important;">Leave this field empty if you're human: <input type="text" name="_mc4wp_honeypot" value="" tabindex="-1" autocomplete="off"></label><input type="hidden" name="_mc4wp_timestamp"
value="1714392162"><input type="hidden" name="_mc4wp_form_id" value="869"><input type="hidden" name="_mc4wp_form_element_id" value="mc4wp-form-2">
<div class="mc4wp-response"></div>
</form>POST
<form id="mc4wp-form-3" class="mc4wp-form mc4wp-form-869" method="post" data-id="869" data-name="Marijuana News In Your Inbox">
<div class="mc4wp-form-fields">Get our daily newsletter. <p>
<label>Email address: </label>
<input type="email" name="EMAIL" placeholder="Your email address" required="">
</p>
<p>
<input type="submit" value="Sign up">
</p>
</div><label style="display: none !important;">Leave this field empty if you're human: <input type="text" name="_mc4wp_honeypot" value="" tabindex="-1" autocomplete="off"></label><input type="hidden" name="_mc4wp_timestamp"
value="1714392162"><input type="hidden" name="_mc4wp_form_id" value="869"><input type="hidden" name="_mc4wp_form_element_id" value="mc4wp-form-3">
<div class="mc4wp-response"></div>
</form>Text Content
* Politics
* Science & Health
* Culture
* Business
* Video
* Newsletter
* Subscribe
* Remove Ads
* Bill Tracking
* About
* Login Instructions
* All 2024 Cannabis Bills
* Bill Hearing Calendar
* About Marijuana Moment
* Support Marijuana Moment
* Subscribe To Newsletter
Connect with us
*
*
*
MARIJUANA MOMENT
FEDS ANNOUNCE PLAN TO FUND RESEARCH ON USING PSYCHEDELICS TO TREAT CHRONIC PAIN
IN OLDER ADULTS
* Politics
* Amendment Narrows Scope Of California Bill To Remove Marijuana Employment
Protections For Law Enforcement
* New Mexico Governor ‘Offended’ By Top Biden Official’s Reaction To
Marijuana Business Seizure Concerns, Leaked Audio Shows
* Congress Will Not Pursue Marijuana Banking Reform Through Must-Pass
Aviation Bill, Industry Group Says
* Kansas Senate Rejects Motion To Revive Medical Marijuana Legalization Bill
* Biden Campaign Says Trump ‘Took Marijuana Reform Backwards’ By Rescinding
Enforcement Memo, Despite Current Admin Failing To Reinstate It
* Science & Health
* Feds Announce Plan To Fund Research On Using Psychedelics To Treat Chronic
Pain In Older Adults
* ‘No Evidence’ That Marijuana Legalization For Adults Increases Youth
Cannabis Use, New Research Published By American Medical Association Finds
* State Marijuana Legalization Linked To Fewer Immigrant Deportations, Study
Finds
* CBD Is A ‘Powerful And Promising’ Treatment For Crack Use Disorder—With
Fewer Side Effects Than Conventional Therapies, Study Finds
* Marijuana Legalization Reduces Likelihood Of Teen Use, Study Published By
American Medical Association Finds
* Culture
* Brands And Advocacy Groups—From ACLU To KFC—Launch 4/20 Promotions To Mark
The Marijuana Holiday
* Former Minnesota Gov. Jesse Ventura Promotes New Cannabis Brand Ahead Of
4/20 That He’d ‘Offer To You’ On Governor’s Mansion Visit
* Colorado Amendment Addresses Concerns On Banning Social Media Marijuana
Posts, But Questions On Psychedelics And Other Drugs Remain
* Former Minnesota Governor Jesse Ventura Launches His Own Cannabis Brand,
Fulfilling A ‘Lifelong Dream’
* Marijuana Rolling Paper Company Seeks Content Creator To ‘Get Paid To
Smoke Weed’ For $70,420 Salary
* Business
* Massachusetts Saw Record-Breaking Marijuana Sales On 4/20, Pushing State
Across $6 Billion Mark For Recreational Purchases
* Legal Marijuana Purchases In Michigan Spiked In March, Reaching A New
Record High
* The Legal Marijuana Industry Now Supports More Than 440,000 Full-Time
Jobs, Up 5% From Last Year, Report Finds
* Missouri Warns Marijuana License Applicants Of ‘Predatory Practices’
Around Social Equity Status
* Missouri Marijuana Worker Union Dispute Could Have Major Implications For
National Labor Law
* Video
* New Hampshire Senate President Wants Changes To Marijuana Legalization
Bill Passed By House
* Texas Governor Condemns Local Marijuana Decriminalization Efforts As
Lubbock Voters Decide On Reform At The Ballot
* VP Kamala Harris Highlights Marijuana Pardons At Another White House Event
With Presidential Clemency Recipients
* Pennsylvania Lawmakers Press Liquor Regulator About State’s Ability To Run
Marijuana Shops During Joint Legalization Hearing
* Key Congresswoman Says ‘Now Is The Time’ To Pass Marijuana Banking Bill,
Despite McConnell’s ‘Concerns’
* Newsletter
* NM gov slams fed cannabis seizures in her state (Newsletter: April 29,
2024)
* Lawmakers push DEA to act on cannabis (Newsletter: April 26, 2024)
* Legalizing cannabis doesn’t increase youth use, AMA study finds
(Newsletter: April 25, 2024)
* Biden & Trump voters’ cannabis views (Newsletter: April 24, 2024)
* Progressives plan cannabis votes under Democratic majority (Newsletter:
April 23, 2024)
* Subscribe
* Remove Ads
* Bill Tracking
* About
* Login Instructions
* All 2024 Cannabis Bills
* Bill Hearing Calendar
* About Marijuana Moment
* Support Marijuana Moment
* Subscribe To Newsletter
SCIENCE & HEALTH
FEDS ANNOUNCE PLAN TO FUND RESEARCH ON USING PSYCHEDELICS TO TREAT CHRONIC PAIN
IN OLDER ADULTS
Published
14 seconds ago
on
April 29, 2024
By
Ben Adlin
A new federal funding opportunity from the National Institutes of Health (NIH)
will use $8.4 million to support clinical trials on the safety and efficacy of
psychedelic-assisted therapy to treat chronic pain in older adults.
An NIH notice of funding opportunity posted on Wednesday says the research can
include “classic” psychedelics—including psilocybin, DMT, LSD and mescaline—as
well as similar compounds such as MDMA. Cannabis and ketamine are not considered
psychedelics for the purposes of the clinical trials.
“Approximately 40% of older Americans report living with chronic pain,” the
funding notice says, with treatment of pain later in life—involving
acetaminophen, NSAIDs, opioids and other drugs, along with behavioral therapy,
physical activity, acupuncture and electrical stimulation— being “complex and
often inadequate.”
CBD's Potential To Treat Cancer, Schizophrenia, And COVID
CBD's Potential To Treat Cancer, Schizophrenia, And COVID
New research from South Korea highlights the potential of CBD to treat an array
of conditions from cancer to schizophrenia to COVID. The plant and CBD exhibit
"neuroprotective, anti-inflammatory, anti-thrombotic, anti-bacterial, and
antiepileptic properties". Cannabinoids are also said to have "diverse
anticancer properties" and present "promising opportunities for future cancer
treatment" It's also a promising pain relief alternative, a way to manage the
symptoms of schizophrenia, and a possible inhibitor of COVID-19. CBD has
benefits for diabetes-related conditions which could be impactful on a
significant 11.6% of the US population who have diabetes. As more research is
conducted a growing amount of applications are being found for CBD and hemp,
such as pharmaceutical drugs, skincare, and fuel.
More Videos
0 seconds of 1 minute, 8 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
Keyboard ShortcutsEnabledDisabled
Shortcuts Open/Close/ or ?
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
Next Up
CBD ‘Powerful and Promising’ Treatment Option for Crack Addiction
01:06
facebook twitter Email pinterest
Linkhttps://cdn.jwplayer.com/previews/4CNqIuiD
Copied
Live
00:00
01:00
01:08
“A potential novel approach to treatment of chronic pain in adults involves
psychedelic-assisted therapy (PAT),” it continues. “Research with psychedelics
was inspired by millennia of Indigenous experience incorporating sacred plant
medicines in ceremonial healing practices.”
More recently, the notice says, “Evidence for the efficacy of PAT has been
particularly notable in depression, anxiety (especially existential distress),
post-traumatic stress disorder (PTSD), and substance use disorders, among other
indications.”
The grant, which will be overseen by NIH component agencies the National
Institute on Aging (NIA) and the National Center for Complementary and
Integrative Health (NCCIH), will award up to $3.4 million per year in fiscal
2025–2026 and up to $5 million per year in fiscal 2027–2029. The broad range of
eligible organizations includes colleges and universities, nonprofits,
for-profit businesses, state or local governments, federal agencies and others,
such as school districts or tribal organizations.
The new funding is aimed at supporting a “clinical trials network involving
multiple institutions collecting safety and early efficacy data” among older
people with chronic pain.
“The first phase will involve safety and efficacy study in older adults, and the
second phase will involve expanded safety and efficacy studies in older adults
with chronic pain conditions,” the NIH posting says. “This funding structure is
expected to lead to a higher level of collaboration, planning, and harmonization
than would be possible through multiple individually funded grants.”
The federal agency notes that while “previous studies of PAT have included
limited numbers of older adults who have tolerated treatment well without
significant adverse effects, more focused safety and efficacy studies in older
adults are needed.”
Applications for the new grant money can be submitted as of September 10. The
application window will close a month later, on October 10. The earliest start
date for the work is set for July 2025.
Recently, a separate study published by the American Medical Association found
that single-dose psilocybin use was “not associated with risk of paranoia,”
while other adverse effects such as headaches are generally “tolerable and
resolved within 48 hours.”
That study, published in JAMA Psychiatry earlier this month, involved a
meta-analysis of double-blind clinical trials where psilocybin was used to treat
anxiety and depression from 1966 to last year.
AMA published a separate study last month that similarly contradicted commonly
held beliefs about the potential risks of psychedelics use, finding the
substances “may be associated with lower rates of psychotic symptoms among
adolescents.”
Also, result of a clinical trial published by AMA in December “suggest efficacy
and safety” of psilocybin-assisted psychotherapy for treatment of bipolar II
disorder, a mental health condition often associated with debilitating and
difficult-to-treat depressive episodes.
The association also published research last August that found people with major
depression experienced “clinically significant sustained reduction” in their
symptoms after just one dose of psilocybin.
Another recent study suggests that the use of full-spectrum psychedelic mushroom
extract has a more powerful effect than chemically synthesized psilocybin alone,
which could have implications for psychedelic-assisted therapy. The findings
imply that the experience of entheogenic mushrooms may involve a so-called
“entourage effect” similar to what’s observed with cannabis and its many
components.
> ‘No Evidence’ That Marijuana Legalization For Adults Increases Youth Cannabis
> Use, New Research Published By American Medical Association Finds
Photo courtesy of Wikimedia/Workman.
Marijuana Moment is made possible with support from readers. If you rely on our
cannabis advocacy journalism to stay informed, please consider a monthly Patreon
pledge.
Related Topics:featured
Don't Miss
‘No Evidence’ That Marijuana Legalization For Adults Increases Youth Cannabis
Use, New Research Published By American Medical Association Finds
Ben Adlin
Ben Adlin, a senior editor at Marijuana Moment, has been covering cannabis and
other drug policy issues professionally since 2011. He was previously a senior
news editor at Leafly, an associate editor at the Los Angeles Daily Journal and
a Coro Fellow in Public Affairs. He lives in Washington State.
YOU MAY LIKE
NM gov slams fed cannabis seizures in her state (Newsletter: April 29, 2024)
Amendment Narrows Scope Of California Bill To Remove Marijuana Employment
Protections For Law Enforcement
New Mexico Governor ‘Offended’ By Top Biden Official’s Reaction To Marijuana
Business Seizure Concerns, Leaked Audio Shows
Congress Will Not Pursue Marijuana Banking Reform Through Must-Pass Aviation
Bill, Industry Group Says
Kansas Senate Rejects Motion To Revive Medical Marijuana Legalization Bill
Biden Campaign Says Trump ‘Took Marijuana Reform Backwards’ By Rescinding
Enforcement Memo, Despite Current Admin Failing To Reinstate It
Advertisement
MARIJUANA NEWS IN YOUR INBOX
Get our daily newsletter.
Email address:
Leave this field empty if you're human:
SUPPORT MARIJUANA MOMENT
*
*
*
* About Marijuana Moment
* Subscribe
* Sponsorship and Advertising
* Privacy Policy
All the cannabis news you need, all in one place. Copyright © 2017-2024
Marijuana Moment LLC ® and Tom Angell
Information from your device can be used to personalize your ad experience.
Do not sell or share my personal information.
A Raptive Partner Site
MARIJUANA NEWS IN YOUR INBOX
Get our daily newsletter.
Email address:
Leave this field empty if you're human:
✕
Do not sell or share my personal information.
You have chosen to opt-out of the sale or sharing of your information from this
site and any of its affiliates. To opt back in please click the "Customize my ad
experience" link.
This site collects information through the use of cookies and other tracking
tools. Cookies and these tools do not contain any information that personally
identifies a user, but personal information that would be stored about you may
be linked to the information stored in and obtained from them. This information
would be used and shared for Analytics, Ad Serving, Interest Based Advertising,
among other purposes.
For more information please visit this site's Privacy Policy.
CANCEL
CONTINUE